| Galectin-3 Protein | |
|---|---|
| Full Name | Galectin-3 (LGALS3) |
| Gene Symbol | LGALS3 |
| Protein Family | Galectin family (beta-galactoside-binding lectins) |
| Location | Chromosome 14q22.3 |
| Molecular Weight | 29.8 kDa |
| Function | Lectin, cell adhesion, immune regulation, autophagy |
Galectin-3 (encoded by the LGALS3 gene) is a unique member of the galectin family of beta-galactoside-binding lectins. Unlike other galectins that share a common carbohydrate-recognition domain (CRD), galectin-3 has a distinct structure consisting of an N-terminal proline-rich region followed by a C-terminal CRD. This configuration enables galectin-3 to form multimers and cross-link glycoconjugates on cell surfaces and extracellular matrix proteins[@barondes1994][@cooper2002].
Galectin-3 is expressed in various cell types including immune cells (macrophages, microglia, dendritic cells), epithelial cells, endothelial cells, and neurons. It participates in diverse biological processes including cell adhesion, cell growth, apoptosis, inflammation, immune response, and autophagy. In the central nervous system, galectin-3 is expressed in neurons, astrocytes, and particularly in activated microglia, where it serves as a key marker of microglial activation[@burguillos2015][@chen2021].
The role of galectin-3 in neurodegenerative diseases has attracted considerable attention. It participates in neuroinflammation, protein aggregation, neuronal survival, and autophagy—processes central to diseases like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis[@sanchez2019][@tan2020].
The LGALS3 gene is located on chromosome 14q22.3 and spans approximately 17 kb. The gene consists of 6 exons encoding a 251-amino acid protein with a molecular weight of approximately 29.8 kDa[@schnebert1998].
Galectin-3 has a distinctive structure:
N-terminal Domain: Contains 6-8 repeats of 6-12 amino acids rich in proline, glycine, and tyrosine. This flexible domain mediates multimerization and protein-protein interactions.
C-terminal Carbohydrate-Recognition Domain (CRD): The ~130 amino acid CRD binds beta-galactosides with affinity for N-acetyllactosamine (LacNAc) residues on glycoproteins and glycolipids.
In the normal brain, galectin-3 is expressed at low levels:
Galectin-3 functions as a lectin that binds to surface glycoproteins and glycolipids, mediating cell-cell and cell-matrix adhesion[@cooper2002]:
Cell-Cell Adhesion: Galectin-3 can cross-link glycoconjugates on adjacent cells, promoting aggregation.
Cell-Matrix Adhesion: Binds to integrins and other matrix receptors, modulating adhesion to extracellular matrix.
Cell Migration: Regulates cell motility through interactions with cytoskeletal proteins and signaling molecules.
Galectin-3 is a key regulator of immune responses[@yang2011][@liu2004]:
Macrophage/Microglia Activation: Galectin-3 serves as a marker and regulator of activated microglia. It promotes pro-inflammatory signaling and phagocytosis.
T Cell Function: Modulates T cell activation, differentiation, and apoptosis.
Cytokine Production: Regulates production of inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6.
Autoimmunity: Dysregulated galectin-3 expression is associated with autoimmune conditions.
Galectin-3 has complex, context-dependent effects on cell death[@cooper2002]:
Anti-apoptotic Functions: In some contexts, galectin-3 translocates to the mitochondria and inhibits apoptosis through interactions with Bcl-2 family proteins.
Pro-apoptotic Effects: Under certain conditions, galectin-3 can promote apoptosis.
Cell Survival Pathways: Activates signaling pathways including PI3K/Akt that promote cell survival.
Galectin-3 participates in autophagy, the cellular degradation system that is impaired in neurodegenerative diseases[@kim2018]:
Autophagosome Formation: Galectin-3 localizes to autophagosomes and regulates their formation and maturation.
Lysosomal Function: Modulates lysosomal activity and function.
Selective Autophagy: Involved in selective degradation of damaged organelles and protein aggregates.
Galectin-3 has emerged as an important player in Alzheimer's disease pathogenesis through multiple mechanisms[@sanchez2019][@tan2020][@pasqualetti2019]:
Microglial Activation: Galectin-3 is highly upregulated in activated microglia surrounding amyloid plaques. This activation state promotes neuroinflammation through production of pro-inflammatory cytokines and reactive oxygen species. The sustained inflammatory response contributes to neuronal damage.
Amyloid-beta Metabolism: Galectin-3 interacts with amyloid-beta peptides and affects their aggregation and clearance. Studies show that galectin-3 can accelerate amyloid-beta aggregation while also modulating its degradation by microglia.
Tau Pathology: Galectin-3 expression correlates with tau pathology in Alzheimer's disease brains. It may contribute to tau phosphorylation, aggregation, and spread between neurons. Pasqualetti et al. demonstrated that galectin-3 colocalizes with neurofibrillary tangles and may promote tau pathology.
Neuronal Survival: Iwata et al. showed that galectin-3 modulates amyloid-beta toxicity in neurons. The effects are complex—galectin-3 can be protective in some contexts while contributing to damage in others.
Biomarker Potential: Galectin-3 has been investigated as a blood and CSF biomarker for Alzheimer's disease. Elevated galectin-3 levels in CSF correlate with disease progression and cognitive decline[@fernandez2021].
In Parkinson's disease, galectin-3 is involved in neuroinflammation and alpha-synuclein pathology[@boza2020]:
Microglial Activation: Activated microglia expressing galectin-3 are found in the substantia nigra and other brain regions affected in PD. This activation contributes to dopaminergic neuron loss.
Alpha-synuclein Aggregation: Galectin-3 interacts with alpha-synuclein and may influence its aggregation and clearance. The protein is detected in Lewy bodies, the pathological inclusions characteristic of PD.
Neuroinflammation: Promotes production of inflammatory mediators that damage dopaminergic neurons.
Therapeutic Implications: Targeting galectin-3 may provide neuroprotective benefits by reducing microglial activation and promoting protein clearance.
Galectin-3 is implicated in ALS and other motor neuron diseases[@yang2021]:
Microglial Activation: Activated microglia expressing galectin-3 are present in ALS spinal cord and brain.
Neuroinflammation: Promotes inflammatory processes that contribute to motor neuron degeneration.
Protein Aggregation: May interact with TDP-43 and other aggregation-prone proteins in ALS.
Galectin-3 is involved in various protein aggregation disorders[@lee2021]:
Prion Diseases: Galectin-3 is upregulated in prion disease and may modulate prion protein aggregation and spread.
Huntington's Disease: Implicated in mutant huntingtin aggregation and toxicity.
Frontotemporal Dementia: Associated with TDP-43 pathology.
Galectin-3 is a key mediator of neuroinflammation in neurodegenerative diseases[@burguillos2015][@chen2021]:
Microglial Activation: Galectin-3 is both a marker and a functional regulator of pro-inflammatory microglial activation. It triggers signaling cascades including NF-κB activation and MAPK pathways.
Cytokine Storm: Promotes production of TNF-alpha, IL-1beta, IL-6, and other pro-inflammatory cytokines.
Nitric Oxide Production: Enhances inducible nitric oxide synthase (iNOS) expression and nitric oxide production.
Matrix Remodeling: Modulates extracellular matrix remodeling through interactions with integrins and other proteins.
Galectin-3 is involved in oxidative stress responses in neurons[@menez2019]:
Mitochondrial Function: Modulates mitochondrial dynamics and function.
ROS Production: Can promote reactive oxygen species generation in activated microglia.
Antioxidant Responses: May activate Nrf2 and other antioxidant pathways.
Galectin-3 affects synaptic function and plasticity[@song2017]:
Synapse Formation: Modulates synaptic development and connectivity.
Synaptic Plasticity: Involved in long-term potentiation and memory formation.
Synapse Loss: Microglial galectin-3 may contribute to synapse elimination in neurodegenerative conditions.
Galectin-3 affects the blood-brain barrier in neurodegeneration[@yan2019]:
Barrier Integrity: Modulates tight junction proteins and endothelial function.
Leukocyte Trafficking: Promotes infiltration of peripheral immune cells into the CNS.
Peripheral-CNS Communication: Mediates interactions between peripheral immune signals and brain responses.
Immunohistochemistry: Detects galectin-3 in brain tissue sections, revealing cellular localization and relationship to pathology.
ELISA: Measures galectin-3 levels in cerebrospinal fluid and blood as potential biomarkers.
Western Blot: Quantifies protein levels in tissue and cell samples.
qPCR: Measures LGALS3 gene expression.
Knockout Mice: Galectin-3 knockout mice reveal its role in neuroinflammation and disease.
Cell Culture: Primary neurons, microglia, and cell lines for mechanistic studies.
CRISPR/Cas9: Genetic manipulation to study galectin-3 functions.
Small Molecule Inhibitors: Pharmacological inhibitors of galectin-3 binding.
Antisense Oligonucleotides: siRNA and antisense approaches to reduce expression.
Antibody Therapy: Anti-galectin-3 antibodies for research and potential therapy.
Galectin-3 is being evaluated as a biomarker for neurodegenerative diseases[@tan2020][@fernandez2021]:
CSF Biomarker: Elevated CSF galectin-3 correlates with disease severity in AD and other dementias.
Blood Biomarker: Peripheral galectin-3 measurements show promise for disease diagnosis and progression monitoring.
Diagnostic Utility: Combines with other biomarkers for improved diagnostic accuracy.
Targeting galectin-3 represents a therapeutic strategy for neurodegenerative diseases[@bhardwaj2020]:
Anti-inflammatory Therapy: Reducing galectin-3-mediated microglial activation.
Protein Clearance: Enhancing autophagy to clear aggregated proteins.
Neuroprotection: Blocking pro-death effects while preserving beneficial functions.
Challenges include the complex, context-dependent roles of galectin-3 and ensuring that targeting it does not disrupt normal physiological functions.
Galectin-3 interacts with numerous proteins:
Apoptotic Proteins: Bcl-2, Apaf-1 in apoptosis regulation
Signal Transduction: EGFR, integrins in cell signaling
Cytoskeletal Proteins: Actin, tubulin in cell structure
Glycoproteins: Various cell surface and extracellular matrix proteins
Galectin-3 modulates multiple pathways:
NF-κB Pathway: Activates pro-inflammatory gene expression
MAPK Pathways: ERK, JNK, p38 in stress responses
PI3K/Akt Pathway: Affects cell survival and metabolism
Wnt/β-catenin Pathway: Modulates developmental and修复 pathways
Mice lacking LGALS3 have been instrumental in understanding its functions:
Reduced Inflammation: Knockout mice show diminished microglial activation in response to injury.
Altered Immunity: Defects in macrophage function and inflammatory responses.
Behavioral Changes: Some studies report memory and motor deficits.
Galectin-3 is studied in various animal models:
APP/PS1 Mice: Amyloid deposition with galectin-3+ microglia
MPTP Model: Parkinson's disease model with galectin-3 involvement
SOD1 Mice: ALS model with galectin-3 in activated microglia
Key questions remain:
Areas of active investigation include: